Comprehensive evidence for the pathogenicity of the BRCA2 c.7847C>T (p.Ser2616Phe) variant specific to the Japanese population.
Summary
This nationwide Japanese study resolved the status of the BRCA2 c.7847C>T (p.Ser2616Phe) variant, which is specific to the Japanese population and was previously of uncertain significance. By integrating quantitative cosegregation analyses, robust functional evidence, and population frequency data, researchers accumulated strong evidence. The evaluation led to the reclassification of this variant as "Pathogenic" according to the ClinGen ENIGMA framework. This reclassification is crucial for ensuring eligible Japanese patients gain access to appropriate targeted therapies, such as PARP inhibitors.
Analysis
The reclassification of the BRCA2 c.7847C>T variant as pathogenic represents a significant step forward for precision medicine in Japan. It enables patients carrying this genetic alteration, which is specific to the Japanese population, to access PARP inhibitors. These targeted therapies were previously unavailable due to the variant's uncertain classification. This highlights the critical importance of population-specific genetic studies to adapt companion diagnostics and optimize therapeutic strategies in oncology.